吉利德科学(GILD)今日盘前大涨5.24%，引发投资者关注。这一涨幅主要源于公司发布的强劲财报以及分析师对其新药的积极评价。
根据公司公布的2025年第二季度财报，吉利德科学实现调整后每股收益2.01美元，超过分析师预期的1.96美元。季度收入同比增长2%至70.8亿美元，同样高于市场预期的69.8亿美元。公司还上调了全年销售预期，预计全年产品销售额在283亿美元至287亿美元之间。
此外，华尔街分析师对吉利德科学新推出的艾滋病预防药物Yeztugo持乐观态度。摩根大通分析师表示，公司在PrEP（艾滋病暴露前预防）领域推出Yeztugo的评论传递了信心，表明迄今为止的推出趋势令人鼓舞。伯恩斯坦预测PrEP市场已经成熟，Yeztugo的上市将取得成功。这些积极因素共同推动了吉利德科学股价的大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.